Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5310)
All Articles published online
|
Publishing Process of This Article
|
Feb 6, 2020 (publication date) through Jul 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Jiang Q, Xie MX, Zhang XC. Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with HER2 gene amplification: A case report. World J Clin Cases 2020; 8(3): 594-599 [PMID: 32110671 DOI: 10.12998/wjcc.v8.i3.594] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v8/i3/594.htm |
| Number | Citing Articles |
| 1 |
Nada Albarakati, Alaa Al‐Shareeda, Majed Ramadan, Batla Al‐Sowayan, Ola Negm, Taoufik Nedjadi. Interaction between HER2 and ATM predicts poor survival in bladder cancer patients. Journal of Cellular and Molecular Medicine 2022; 26(19): 4959 doi: 10.1111/jcmm.17512
|
| 2 |
Shihao Shang, Lei Zhang, Kepu Liu, Maoxin Lv, Jie Zhang, Dongen Ju, Di Wei, Zelong Sun, Pinxiao Wang, Jianlin Yuan, Zheng Zhu. Landscape of targeted therapies for advanced urothelial carcinoma. Exploration of Targeted Anti-tumor Therapy 2024; 5(3): 641 doi: 10.37349/etat.2024.00240
|
| 3 |
Giorgio Patelli, Annalisa Zeppellini, Francesco Spina, Elena Righetti, Stefano Stabile, Alessio Amatu, Federica Tosi, Silvia Ghezzi, Salvatore Siena, Andrea Sartore-Bianchi. The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives. Cancer Treatment Reviews 2022; 104: 102351 doi: 10.1016/j.ctrv.2022.102351
|
| 4 |
Chia-Hsien Shih, Yu-Hua Lin, Hao-Lun Luo, Wen-Wei Sung. Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1326296
|
| 5 |
Danijel Sikic, Markus Eckstein, Veronika Weyerer, Jennifer Kubon, Johannes Breyer, Florian Roghmann, Frank Kunath, Bastian Keck, Philipp Erben, Arndt Hartmann, Ralph M. Wirtz, Bernd Wullich, Helge Taubert, Sven Wach. High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations 2022; 40(2): 63.e9 doi: 10.1016/j.urolonc.2021.06.021
|
| 6 |
Dong Chen, Yunlin Ye, Shengjie Guo, Kao Yao. Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer. Frontiers in Molecular Biosciences 2021; 8 doi: 10.3389/fmolb.2021.800945
|
| 7 |
Peipei Shang, Cheng Lou, Lei Yin, Chenjie Tao, Yulong Dong, Guang Yang, Zhengang Yuan. Advanced renal pelvis carcinoma patient with an ERBB2 insertion mutation: a case report. Journal of International Medical Research 2023; 51(11) doi: 10.1177/03000605231204502
|
| 8 |
Meiting Chen, Kai Yao, Manming Cao, Hao Liu, Cong Xue, Tao Qin, Lingru Meng, Zhousan Zheng, Zike Qin, Fangjian Zhou, Zhuowei Liu, Yanxia Shi, Xin An. HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study. Cancer Immunology, Immunotherapy 2023; 72(7): 2309 doi: 10.1007/s00262-023-03419-1
|
| 9 |
Yao Chang, Delong Zhao, Zicheng Wang, Kejia Zhu, Andong Guo, Jishuang Cao, Chenrui Wu, Sentai Ding. Expression of HER2 in urothelial carcinoma and its significance. Current Urology 2024; doi: 10.1097/CU9.0000000000000249
|
| 10 |
Yi-Xin Zhou, Jia-Ling Wang, Xiao-Li Mu, Ya-Juan Zhu, Ye Chen, Ji-Yan Liu. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study. Aging 2023; doi: 10.18632/aging.205382
|